Biomedical subjects

Cetin Yildirim

Publications and source records attributed to Cetin Yildirim.

3 recordsLinked to original sources

PubMed2006

Does thyroid replacement therapy affect pulmonary function tests in patients with subclinical hypothyroidism?

OBJECTIVE: Subclinical hypothyroidism is an elevation in serum thyroid-stimulating hormone (TSH) while having normal serum free thyroxine (FT4) and triiodothyronine (FT3) levels. The purpose of this prospective observational study was to evaluate the pulmonary function of patients diagnosed with subclinical hypothyroidism, both before and after treatment with thyroid hormone. METHODS: This study took place at the Medical Faculty, Celal Bayar University, Manisa, Turkey between February 2003 and June 2004. Thirty-eight patients (37 females, one male) with subclinical hypothyroidism between 20 and 65 years of age were included in the study. Most were mildly obese. Arterial blood gases and pulmonary function tests were performed before treatment with thyroid hormone, and afterwards, the TSH value reached the normal range (indicating euthyroidism). RESULTS: Oxygen saturation, but not partial oxygen pressure or partial carbon dioxide pressure, was statistically, but not clinically significantly higher after treatment with thyroid hormone (p=0.01). Pulmonary function tests were not significantly different before and after treatment with thyroid hormone. CONCLUSION: In our subclinical hypothyroidism patients, pulmonary function tests were normal and did not significantly change with thyroid hormone replacement. The advantages of thyroid hormone replacement therapy, at least regarding respiratory function, seem to be clearly present in patients with overt, clinical hypothyroidism but not in patients with subclinical hypothyroidism.

Adult↗

PubMed2006

[The protective effect of oral magnesium supplement on noise-induced hearing loss].

OBJECTIVES: We investigated the beneficial effect of magnesium in the prevention of noise-induced cochlear damage in guinea pigs by transient evoked otoacoustic emissions (TEOAE). STUDY DESIGN: Thirty-nine guinea pigs with normal auropalpebral reflex were randomly divided into control (n=20) and study (n=19) groups. All the animals were subjected to wide-band noise standardized at a mean of 98+/-2 dB for 16 hours a day for 10 days in a sound isolated cabin. The study animals received 39 mmol/l MgCl2 throughout the study period starting from 15 days before noise exposure. Otomicroscopic examination, auditory brain stem response (ABR) and TEOAE measurements were performed before and after noise exposure. Tympanometric measurements were performed to eliminate possible middle ear pathologies. RESULTS: Although the mean TEOAE response and reproducibility values showed significant decreases after noise application in the control group (p<0.001), they were not affected significantly in magnesium-treated animals. Post-exposure mean TEOAE response and reproducibility values significantly differed between the two groups (p<0.001). Noise-induced elevations in ABR thresholds were significant in both groups (p<0.001); however, it was noted that hearing levels were better preserved in the study group. CONCLUSION: Our data suggest that oral magnesium intake may be beneficial in the prevention of cochlear damage in noise-induced hearing loss.

Administration, Oral↗

PubMed2005

[Evaluation of the protective effect of magnesium on amikacin ototoxicity by electrophysiologic tests in guinea pigs].

OBJECTIVES: This experimental study was performed to evaluate the protective effect of magnesium on amikacin ototoxicity. STUDY DESIGN: Twenty-seven guinea pigs (54 ears) with normal auropalpebral reflexes and otomicroscopic examination, auditory brain stem responses (ABR), and transient evoked otoacoustic emissions (TEOAE) were randomly divided into four groups to receive amikacin once 15 mg/kg daily (group 1 and 3) and twice 7.5 mg/kg daily (group 2 and 4) for seven days. Groups 3 and 4 were administered oral MgCl an hour after amikacin use at a dose of 39 mmol/l and 19.5 mmol/l, respectively, for seven days. Otomicroscopic examination, ABR and TEOAE measurements were repeated on the third, fifth, and seventh days. RESULTS: Compared to group 1, decreases in TEOAE amplitudes and reproducibility and increases in ABR thresholds were significant in group 2 (p<0.05). However, in groups 3 and 4, TEOAE amplitudes remained unchanged, or even increased and the reproducibility of TEOAE responses and ABR thresholds showed no significant changes (p>0.05). CONCLUSION: Our data show that oral magnesium may play a protective role on amikacin ototoxicity.

Administration, Oral↗